drugset / Trial / NCT00565240
Mid-luteal Phase Synchronization of Ovarian Folliculogenesis in Women
Completed
41 enrolled
University of Saskatchewan
Canadian Institutes of Health Research (CIHR) · collab
RandomizedSingle-groupOpen-labelHealth-services research
Summary
We hypothesize that administration of an aromatase inhibitor (AI) and hormonal contraceptives (HC) in the mid-luteal phase of the menstrual cycle will result in atresia of the follicles in the extant wave and cause synchronous re-emergence of a new follicular wave. We anticipate that this will provide us with information to facilitate the development of a new method for ovarian synchronization; a safer, more effective ovulation induction therapy; a new method for emergency contraception; and a greater understanding of human folliculogenesis.
Timeline
- Start
- 2007-11
- Primary completion
- 2009-09
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Letrozole | Other / unclassified | — | — |
| Subject | Marvelon | Small molecule | — | Oral |
| Subject | NuvaRing | Other / unclassified | — | Other |
Indications
No indication recorded.